Post transplant lymphoproliferative disease (PTLD) is a type of B-cell non-Hodgkin lymphoma
that occurs in patients with weakened immune systems due to immunosuppressive medications
taken after organ or stem cell transplantation. This is usually related to a virus called
Epstein-Barr (EPV). Rituximab is a type of drug called an "antibody" that specifically
destroys both normal and cancerous B-cells, and is commonly used for PTLD. Bortezomib is a
drug that has been approved by the Food and Drug Administration (FDA) to treat multiple
myeloma and a B-cell non-Hodgkin lymphoma called Mantle Cell Lymphoma, and shows significant
activity in lymphoma cells caused by EBV. In this research study, we hope to learn if the
addition of bortezomib to rituximab treatment can increase the rate of complete remissions
and cures of PTLD after organ or stem cell transplant.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Dana-Farber Cancer Institute Millennium Pharmaceuticals, Inc.